4DMT FY2025 net loss $140M; cash $514M; 4D-150 Phase 3 enrollment completed

4D Molecular Therapeutics, Inc.

Net loss of $140M in FY2025 versus $161M in FY2024; R&D expenses $196M (up from $141M).
Cash, equivalents and securities $514M; expected to fund operations into H2 2028.
4D-150 4FRONT-1 Phase 3 wet AMD enrollment completed; topline data expected H1 2027.
Otsuka partnership for 4D-150 in Asia-Pacific provided $85M upfront; up to $336M milestones plus royalties.
Leadership additions: new CFO Kristian Humer, CMO Julie Clark, CTO Katy Barglow, Board member Glenn Sblendorio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.